PD46: Bladder Cancer: Upper Tract Transitional Cell Carcinoma II

Podium Session Moderator(s)

• 

  Seth Lerner, MD

  Vice Chair for Faculty Affairs
  Baylor College of Medicine

Podium Presenter(s)

• 

  Joseph Liao, MD

  Stanford University

Podium Session Moderator(s)

• 

  Firas Petros, MD

  Assistant Professor of Urology / Chief of Urologic Oncology
  The University of Toledo College of Medicine and Life Sciences

Presentations:

• 1:00 PM – 1:10 PM CST

  PD46-01: Detection of individualized mutations and monitoring of postoperative recurrence using circulating tumor DNA in patients with upper tract urothelial carcinoma
  

  Podium Presenter: Daichi Tamura, MD – Iwate Medical University
• 1:10 PM – 1:20 PM CST

  PD46-02: Blood-Based Liquid Biopsy for Diagnosis and Surveillance of Primary Upper Tract Urothelial Carcinoma: Road to Emerging Novel Biomarker
  

  Podium Presenter: Alireza Ghoreifi, MD (he/him/his) – USC
• 1:20 PM – 1:30 PM CST

  PD46-03: Utility of Urinary Tumor DNA Detection in Treatment-Naïve UTUC
  

  Podium Presenter: Facundo M. Davaro, MD
• 1:30 PM – 1:40 PM CST

  PD46-04: A Novel Urine DNA Predictor for Noninvasive Early Diagnosis and Monitoring Minimal Residual Disease of Upper Tract Urothelial Carcinoma
  

  Podium Presenter: Wei Zuo, BA (she/her/hers) – Peking University First Hospital
• 1:40 PM – 1:50 PM CST

  PD46-05: Genetic aberrations identified in focal barbotages– a complementary diagnostic tool in upper tract urothelial carcinoma (UTUC)
  

  Podium Presenter: Tomas Axelsson, MD,Phd – Danderyd Hospital
• 1:50 PM – 2:00 PM CST

  PD46-06: Urological follow-up and mutational patterns in Lynch Syndrome patients: a single center experience
  

  Podium Presenter: Pietro Scilipoti, MD (he/him/his)
• 2:00 PM – 2:10 PM CST

  PD46-07: Urinary comprehensive genomic profiling aids in detection and risk prognosis of upper tract urothelial carcinoma: a case-controlled cohort study
  

  Podium Presenter: Paul Yonover
• 2:10 PM – 2:20 PM CST

  PD46-08: Efficacy and safety of mitomycin gel (UGN-101) as an adjuvant therapy after complete endoscopic management of Upper Tract Urothelial Carcinoma.
  

  Podium Presenter: Craig Labbate
• 2:20 PM – 2:30 PM CST

  PD46-09: Is there a racial disparity in the outcomes of patients with non-metastatic upper tract urothelial carcinoma who are treated surgically? A north american nationwide analysis
  

  Podium Presenter: Ivan Rakic, BS
• 2:30 PM – 2:40 PM CST

  PD46-10: GENDER DISPARITIES IN UPPER TRACT UROTHELIAL CELL CARCINOMA
  

  Podium Presenter: Jeffrey Orf
• 2:40 PM – 2:50 PM CST

  PD46-11: Assessing the Role of Neoadjuvant Chemotherapy in Upper Tract Urothelial Carcinoma Evolution
  

  Podium Presenter: Neeta D'Souza
• 2:50 PM – 3:00 PM CST

  PD46-12: Comparing the perioperative outcomes of open radical nephroureterectomy and Robot assisted nephroureterectomy using propensity score match analysis
  

  Podium Presenter: Sheshang Kamath